









Markets
/
Stocks
/
nasdaq-xrtx
/

XORTX Therapeutics Inc

XRTX

0.625USD

-0.014-2.13%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

2.37MMarket Cap

LossP/E TTM



XORTX Therapeutics Inc

0.625

-0.014-2.13%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of XORTX Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

XORTX Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

255 / 501

Overall Ranking

458 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

14.000

Target Price

+2090.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

XORTX Therapeutics Inc Highlights

StrengthsRisks

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

Fairly Valued

The company’s latest PE is -1.44, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 63.97K shares, decreasing 90.99% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

XORTX Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.61, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -1.44, which is -258.02% below the recent high of 2.28 and -707.14% above the recent low of -11.65.

Score

Industry at a Glance

Previous score

7.61

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 255/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for XORTX Therapeutics Inc is 14.00, with a high of 14.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

14.000

Target Price

+2090.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

XORTX Therapeutics Inc

XRTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.11, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.17 and the support level at 0.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.97

Change

0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.030

Sell

RSI(14)

39.703

Neutral

STOCH(KDJ)(9,3,3)

21.461

Buy

ATR(14)

0.131

High Vlolatility

CCI(14)

-68.401

Neutral

Williams %R

93.672

Oversold

TRIX(12,20)

-1.189

Sell

StochRSI(14)

74.695

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.629

Sell

MA10

0.646

Sell

MA20

0.760

Sell

MA50

0.804

Sell

MA100

0.826

Sell

MA200

0.889

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Davidoff, Allen Warren

120.45K

+7.30%

Citadel Advisors LLC

38.47K

UBS Financial Services, Inc.

20.79K

Giovinazzo (Anthony)

9.63K

National Bank of Canada

3.93K

+2160.92%

Raymond James & Associates, Inc.

500.00

Van Damme (Paul Joseph)

7.11K

Clearstead Advisors LLC

277.00

Spartan Fund Management Inc.

-100.00%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.